Illumina (ILMN) valuation
TrendArc score 50 of 100 · Health 8.6 · Momentum 2.8 · Moat 4.6 · scored Nov 17, 2026 · How the score works
Illumina P/E ratio history
As of November 17, 2026, Illumina trades at 34.9 times its earnings over the last twelve months and 33.8 times the earnings analysts expect over the next twelve. At 7 of its last 10 fiscal year ends its P/E ranged from 24.8 (year to Dec 2025) to 83.2 (year to Jan 2021), with a median of 49.2.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 28, 2025 | $134.95 | $5.45 | 24.8 |
| Dec 29, 2024 | $135.27 | -$7.66 | n/m |
| Dec 31, 2023 | $135.45 | -$7.14 | n/m |
| Jan 1, 2023 | $196.69 | -$27.22 | n/m |
| Jan 2, 2022 | $370.08 | $4.88 | 75.8 |
| Jan 3, 2021 | $359.92 | $4.33 | 83.2 |
| Dec 29, 2019 | $323.24 | $6.57 | 49.2 |
| Dec 30, 2018 | $290.11 | $5.41 | 53.6 |
| Dec 31, 2017 | $212.54 | $4.80 | 44.3 |
| Jan 1, 2017 | $124.55 | $3.01 | 41.4 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
What stands out
- Over the five fiscal years to December 2025, its diluted earnings per share rose from $4.33 to $5.45, 4.7% a year, while its P/E at the fiscal year end went from 83.2 to 24.8.
Each sentence is written by a fixed rule from the figures on this page.
Illumina valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| IlluminaILMN | $30.6B | 34.9 | 33.8 | 6.7 |
| Mettler ToledoMTD | $34.3B | 37.2 | 33.0 | 8.2 |
| IQVIAIQV | $42.4B | 31.4 | 18.5 | 2.5 |
| WatersWAT | $44.2B | 193.0 | 28.0 | 7.9 |
| Agilent TechnologiesA | $48.6B | 33.9 | 26.1 | 6.6 |
| Charles River LaboratoriesCRL | $15.9B | 346.0 | 26.4 | 4.0 |
| Bio-TechneTECH | $11.4B | 66.0 | 34.8 | 9.3 |
| Peer median | 51.6 | 27.2 | 7.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ILMN financials · ILMN returns
No forecast, no recommendation. This page describes Illumina from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.